Compare LTC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTC | SNDX |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 1994 | 2014 |
| Metric | LTC | SNDX |
|---|---|---|
| Price | $39.50 | $20.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $40.00 | $38.69 |
| AVG Volume (30 Days) | 568.1K | ★ 1.5M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 5.96% | N/A |
| EPS Growth | ★ 23.53 | 11.56 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $262,854,000.00 | $172,352,000.00 |
| Revenue This Year | N/A | $107.19 |
| Revenue Next Year | N/A | $41.88 |
| P/E Ratio | $37.60 | ★ N/A |
| Revenue Growth | 25.26 | ★ 627.84 |
| 52 Week Low | $33.64 | $13.00 |
| 52 Week High | $43.00 | $25.59 |
| Indicator | LTC | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 47.70 |
| Support Level | $37.82 | $19.28 |
| Resistance Level | $39.65 | $22.40 |
| Average True Range (ATR) | 0.91 | 1.02 |
| MACD | -0.34 | -0.09 |
| Stochastic Oscillator | 32.34 | 56.81 |
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.